Pulse Biosciences (PLSE) Stock Surges 17% on Major $13M Insider Purchase

TLDR

• Pulse Biosciences (PLSE) shares climbed 16.8% Tuesday following a $13.3 million stock acquisition by two key executives.
• Co-Chairman Robert Duggan acquired 660,233 shares totaling approximately $13 million, while CEO Paul LaViolette purchased 15,000 shares for roughly $295,000.
• Both transactions occurred through the company’s at-the-market equity program during an approved trading period.
• The company specializes in nPulse nanosecond pulsed field ablation technology for atrial fibrillation treatment.
• Year-to-date performance shows PLSE shares climbing nearly 39%, with the company valued at $1.3 billion.

Shares of Pulse Biosciences (PLSE) rallied 16.8% Tuesday following the announcement that two top-level executives purchased a combined $13.3 million worth of company stock.

Pulse Biosciences, Inc., PLSE

The transactions, executed by Co-Chairman Robert Duggan and CEO Paul LaViolette on May 11, 2026, took place during an authorized trading window established by the company.

At press time, shares were trading approximately 13% higher, pushing the year-to-date advance to around 39%.

Duggan dominated the buying activity, securing 660,233 shares for about $13 million. LaViolette contributed by acquiring 15,000 shares valued at approximately $295,350.

Collectively, the executives obtained 675,233 shares via Pulse Biosciences’ at-the-market offering program.

The ATM mechanism allows the company to issue shares directly into public markets. When executives use this avenue to purchase rather than the company to sell, it typically signals strong internal conviction about future prospects.

What Makes This Insider Activity Noteworthy

Insider acquisitions of this magnitude are uncommon. When two senior leaders collectively invest $13.3 million, markets typically pay attention — and respond accordingly.

The timing follows closely behind the company’s Q1 earnings release and new clinical data regarding its nPulse catheter technology.

Wall Street reactions to those developments were split. Some analysts highlighted encouraging clinical performance in European markets and accelerated U.S. pivotal trial schedules. Others pointed to negligible revenue generation, expanding losses, and significant cash consumption.

Despite generating limited commercial sales, Pulse Biosciences commands a $1.3 billion market capitalization.

Understanding PLSE’s Core Business

The company’s flagship technology leverages nanosecond pulsed field ablation — administering extremely brief electrical pulses to eliminate targeted cells while preserving adjacent tissue structures.

Its main therapeutic focus addresses atrial fibrillation, a widespread cardiac rhythm abnormality.

Management has prioritized expediting its U.S. regulatory pathway, with European feasibility trial results serving as an encouraging indicator according to industry analysts.

Daily trading volume for PLSE averages approximately 294,600 shares. Current technical analysis indicators signal a “Strong Buy” rating.

TipRanks’ AI model assigns PLSE a Neutral rating overall, noting that financial weaknesses are counterbalanced by a healthy balance sheet and promising clinical development pipeline.

With a year-to-date gain approaching 39%, the stock significantly outperforms broader market indices as 2026 reaches its midpoint.